We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Details Reasons for Breakthrough Therapy Designation Denials
FDA Details Reasons for Breakthrough Therapy Designation Denials
June 27, 2013
The FDA offered some hints Thursday about why it has denied a third of drugmakers’ breakthrough therapy designation requests, with premature clinical data being the primary culprit.